SecBot SecBot
COURT-RULING ·Filed Jul 9, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonimmediate Processed4mo ago CourtCourt Ruling · govinfo.gov
Court ruling (appellate)
Actionable Insight ▲ Bullish

The Federal Circuit's affirmance permanently eliminates the $107.5M jury verdict and the patent infringement overhang on Tagrisso from these Wyeth patents. Tagrisso is a key AstraZeneca oncology product; this ruling removes a material IP risk. Monitor for any Wyeth petition for certiorari (unlikely given the fact-specific enablement holding) and for any remaining patent challenges on Tagrisso from other parties.

DirectionBullish
Confidencehigh
Horizonimmediate

Drug in focus

AZN drug pipeline →

Tagrisso

● Neutral Named in this court ruling
Impact
Phase
Approved
Time to market
Approved and marketed since 2015 (first FDA approval Nov 2015)
Next catalyst
None dated

What to watchTagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$171.61
T+0 close · Jul 10, 2026 · via day close
Latest settled
−8.79%
T+60 · $156.53
Vs SPY
−11.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $171.61entry
  2. T+1 · 4mo ago −1.25%α −0.48% · $169.47
  3. T+5 · 4mo ago −1.58%α −0.03% · $168.90
  4. T+20 · 3mo ago −5.94%α −8.36% · $161.42
  5. T+60 · 6w ago −8.79%α −11.42% · $156.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Federal Circuit affirmed the district court's grant of JMOL of invalidity for lack of enablement of Wyeth's asserted patents (U.S. Patent 10,603,314 and 10,596,162) covering methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors. The ruling permanently removes the patent infringement risk to AstraZeneca's Tagrisso (osimertinib) and vacates the $107.5M jury verdict against AstraZeneca, eliminating a material liability and IP overhang.

Court Ruling Details

Ruling Date
Jul 9, 2026
Court
United States Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Lourie
Case Type
patent
Ruling Type
final judgment
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Federal Circuit affirmed district court's JMOL of invalidity for lack of enablement of Wyeth's asserted claims in U.S. Patents 10,603,314 and 10,596,162
  • The ruling vacates the $107,500,000 jury verdict against AstraZeneca for induced infringement of Tagrisso (osimertinib)
  • The patents claimed methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors; the court found the specification failed to enable a daily unit dosage for human patients without undue experimentation
  • The Federal Circuit affirmed that the specification provided no working examples of unit dosages in patients and disclosed dosage ranges that were toxic for at least two of the three preferred compounds
  • This is a final appellate ruling from the Federal Circuit, the authoritative court for patent appeals, and is not subject to further appeal as of right

Financial Impact

Vacates $107,500,000 jury verdict against AstraZeneca and permanently removes patent infringement risk on Tagrisso (osimertinib) from these Wyeth patents

liabilityip_risk

Risk Factors

  • Wyeth could petition for certiorari to the Supreme Court, though the fact-specific enablement holding makes this unlikely
  • Other patent challenges to Tagrisso from different patent holders remain possible

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-f42fbd41d9-AZN

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (10h 48m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 10, 2026